Literature DB >> 16819655

[Kala azar. Rare import and significant differential diagnosis].

H Sudeck1.   

Abstract

After traveling into regions endemic for leishmaniasis all patients presenting with generalized febrile symptoms, pancytopenia, hepatosplenomegaly and symptoms as well as laboratory parameters also seen in autoimmune diseases should be screened for leishmaniasis even after a longer time period. Doctors should bear in mind that especially immunosuppressed patients can present with atypical and abortive symptoms and that in this group of patients immune diagnosis is unreliable. A diagnosis of a lymphoma related only to the spleen should not be made and splenectomy must not be carried out before reliable exclusion of kala azar, using modern diagnostic tools like PCR. Patients should be referred to specialized centers e.g. institutes for tropical medicine and therapy must follow actual guidelines, such as the German guidelines published by the AWMF.

Entities:  

Mesh:

Year:  2006        PMID: 16819655     DOI: 10.1007/s00108-006-1674-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  24 in total

Review 1.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

2.  Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Authors:  T K Jha; P Olliaro; C P Thakur; T P Kanyok; B L Singhania; I J Singh; N K Singh; S Akhoury; S Jha
Journal:  BMJ       Date:  1998-04-18

3.  Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study.

Authors:  V Pintado; P Martín-Rabadán; M L Rivera; S Moreno; E Bouza
Journal:  Medicine (Baltimore)       Date:  2001-01       Impact factor: 1.889

4.  Mechanism of anaemia in resistant visceral leishmaniasis.

Authors:  M J Pippard; D Moir; D J Weatherall; H M Lenicker
Journal:  Ann Trop Med Parasitol       Date:  1986-06

Review 5.  Visceral leishmaniasis in a German child who had never entered a known endemic area: case report and review of the literature.

Authors:  C Bogdan; G Schönian; A L Bañuls; M Hide; F Pratlong; E Lorenz; M Röllinghoff; R Mertens
Journal:  Clin Infect Dis       Date:  2000-12-29       Impact factor: 9.079

6.  Mechanism of amphotericin B resistance in Leishmania donovani promastigotes.

Authors:  N Mbongo; P M Loiseau; M A Billion; M Robert-Gero
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

7.  Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm.

Authors:  A J Magill; M Grögl; R A Gasser; W Sun; C N Oster
Journal:  N Engl J Med       Date:  1993-05-13       Impact factor: 91.245

8.  Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial.

Authors:  A S Mazloumi Gavgani; M H Hodjati; H Mohite; C R Davies
Journal:  Lancet       Date:  2002-08-03       Impact factor: 79.321

9.  Haemoculture as a tool for diagnosing visceral leishmaniasis in HIV-negative and HIV-positive patients: interest for parasite identification.

Authors:  J Dereure; F Pratlong; J Reynes; D Basset; P Bastien; J P Dedet
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

10.  Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan.

Authors:  Simon Collin; Robert Davidson; Koert Ritmeijer; Kees Keus; Yosef Melaku; Sammy Kipngetich; Clive Davies
Journal:  Clin Infect Dis       Date:  2004-02-12       Impact factor: 9.079

View more
  1 in total

1.  [Sepsis-like disease in an immunocompromised patient with a travel history to Mallorca].

Authors:  G C Hagenah; T Wündisch; E Eckstein; S Zimmermann; F Holst; W Grimm; A Neubauer; M Lohoff
Journal:  Internist (Berl)       Date:  2007-07       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.